30mCi radioactive iodine achieving comparative excellent response in intermediate/high-risk nonmetastatic papillary thyroid cancer: a propensity score matching study-Reference-Cited by-同舟云学术

30mCi radioactive iodine achieving comparative excellent response in intermediate/high-risk nonmetastatic papillary thyroid cancer: a propensity score matching study

Published:2018-08-25 Issue:3 Volume:62 Page:655-662
ISSN:1355-008X
Container-title:Endocrine
language:en
Short-container-title:Endocrine

Author:

Zhang Yingqiang,Wang Chen,Zhang Xin,Li Hui,Li Xin,Lin Yansong

Funder

National Natural Science Foundation of China

CSCO-Hengrui Research Foundation

Publisher

Springer Science and Business Media LLC

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism

Link

http://link.springer.com/article/10.1007/s12020-018-1724-z/fulltext.html

Reference21 articles.

1. R.L. Siegel, K.D. Miller, A. Jemal, Cancer statistics, 2016. CA Cancer J. Clin. 66(1), 7–30 (2016). https://doi.org/10.3322/caac.21332

2. A.L. Mitchell, A. Gandhi, D. Scott-Coombes, P. Perros, Management of thyroid cancer: United Kingdom national multidisciplinary guidelines. J. Laryngol. Otol. 130(S2), S150–S160 (2016). https://doi.org/10.1017/S0022215116000578

3. B.R. Haugen, E.K. Alexander, K.C. Bible, G. Doherty, S.J. Mandel, Y.E. Nikiforov, F. Pacini, G. Randolph, A. Sawka, M. Schlumberger, K.G. Schuff, S.I. Sherman, J.A. Sosa, D. Steward, R.M. Tuttle, L. Wartofsky, 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. Thyroid, 1–133 (2015), https://doi.org/10.1089/thy.2015.0020

4. U. Mallick, C. Harmer, B. Yap, J. Wadsley, S. Clarke, L. Moss, A. Nicol, P.M. Clark, K. Farnell, R. McCready, J. Smellie, J.A. Franklyn, R. John, C.M. Nutting, K. Newbold, C. Lemon, G. Gerrard, A. Abdel-Hamid, J. Hardman, E. Macias, T. Roques, S. Whitaker, R. Vijayan, P. Alvarez, S. Beare, S. Forsyth, L. Kadalayil, A. Hackshaw, Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. N. Engl. J. Med. 366(18), 1674–1685 (2012). https://doi.org/10.1056/NEJMoa1109589

5. M. Schlumberger, B. Catargi, I. Borget, D. Deandreis, S. Zerdoud, B. Bridji, S. Bardet, L. Leenhardt, D. Bastie, C. Schvartz, P. Vera, O. Morel, D. Benisvy, C. Bournaud, F. Bonichon, C. Dejax, M.E. Toubert, S. Leboulleux, M. Ricard, E. Benhamou, Strategies of radioiodine ablation in patients with low-risk thyroid cancer. N. Engl. J. Med. 366(18), 1663–1673 (2012). https://doi.org/10.1056/NEJMoa1108586

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Outpatient ablation treatment with two doses of 30 mCi of radioactive iodine for non-low-risk papillary thyroid cancer;The Journal of Medical Investigation;2023

2. Urinary iodine concentration and radioactive iodine therapeutic response in patients with differentiated thyroid cancer;Biomarkers in Medicine;2021-08

3. Low-dose radioiodine therapy for patients with intermediate- to high-risk differentiated thyroid cancer;Annals of Nuclear Medicine;2019-12-13